Evidence map›Paper›PMID 38856913›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

Catharanthine, an anticancer vinca alkaloid: an in silico and in vitro analysis of the autophagic system as the major mechanism of cell death in liver HepG2 cells.

Farnoosh Gholami, Bagher Seyedalipour, Nafiseh Heidari-Kalvani, Mohsen Nabi-Afjadi, Mohammad Yaghoubzad-Maleki, Zeinab Fathi, Iraj Alipourfard, Fereshte Barjesteh, Elham Bahreini

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Farnoosh Gholami *Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran.
Bagher Seyedalipour *Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran.
Nafiseh Heidari-KalvaniDepartment of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mohsen Nabi-AfjadiDepartment of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Mohammad Yaghoubzad-MalekiDivision of Biochemistry, Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Zeinab FathiSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Iraj AlipourfardInstitute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland.
Fereshte BarjestehDepartment of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Elham BahreiniDepartment of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. Bahreini.e@iums.ac.ir.ORCID 0000-0001-6823-8638

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Catharanthine, a component of the anticancer drug vinblastine along with vindoline, disrupts the cell cycle by interfering with mitotic spindle formation. Apart from their antioxidant properties, vinca alkaloids like catharanthine inhibit phosphodiesterase activity and elevate intracellular cAMP levels. The aim of this study was to investigate how catharantine affects apoptosis and autophagy. This study conducted experiments on HepG2 liver carcinoma cells with varying doses of catharanthine to evaluate cell death rates and viability and determine the IC

Indexed as

ApoptosisAutophagyMolecular Docking SimulationVinca AlkaloidsAntineoplastic AgentsAntineoplastic Agents, PhytogenicCell SurvivalComputer SimulationDose-Response Relationship, DrugHep G2 CellsHumansLiver NeoplasmsMolecular Dynamics SimulationOxidative StressTOR Serine-Threonine KinasesAntineoplastic AgentsAntineoplastic Agents, PhytogeniccatharanthineTOR Serine-Threonine KinasesVinca AlkaloidsAutophagyBeclin1CatharanthineHepG2LC3

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.